Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) (NCT04675333)

🧪 Interventions in This Study

• evorpacept (DRUG)
• pembrolizumab (DRUG)
• Cisplatin/Carboplatin; 5FU (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (44 Sites)

Showing the first 25 of 44 sites.

• Hoag Hospital — Irvine, California
• University of California San Diego — La Jolla, California
• Cedar Sinai Medical Center — Los Angeles, California
• University of Miami, Sylvester Comprehensive Cancer Center — Miami, Florida
• Moffitt Cancer Center — Tampa, Florida
• Rush University Medical Center — Chicago, Illinois
• University of Louisville — Louisville, Kentucky
• University of Maryland Medical System — Baltimore, Maryland
• Memorial Sloan Kettering — New York, New York
• The Ohio State University — Columbus, Ohio
• Oregon Health & Science University/ Knight Cancer Institute — Portland, Oregon
• Vanderbilt - Ingram Cancer Center — Nashville, Tennessee
• Houston Methodist Cancer Center — Houston, Texas
• Royal Brisbane and Womens Hospital — Herston, Queensland
• Ashford Cancer Centre — Adelaide, South Australia
• Peter MacCallum Cancer Centre — Melbourne, Victoria
• Sir Charles Gairdner Hospital — Nedlands,
• Cliniques Universitaires Saint-Luc — Brussels,
• AZ Groeninge — Kortrijk,
• Amsterdam UMC, Locatie VUMC — Amsterdam,
• Universitair Medisch Centrum Groningen — Groningen,
• National University Cancer Institute — Singapore,
• National Cancer Centre Singapore — Singapore,
• Chungbuk National University Hospital — Cheongju-si,
• Yeungnam University Medical Center — Daegu,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Head and Neck Cancer

• Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity — Boston, Massachusetts
• Imaging With a PET Agent for Detection of Cancers of the Head and Neck — New York, New York
• Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer — Miami, Florida
• ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy — Miami, Florida
• ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer — Bethesda, Maryland
• "QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer — Oklahoma City, Oklahoma

Explore by condition: All Head and Neck Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.